US Secondary Hyperparathyroidism Treatment(SHPT) Market

US Secondary Hyperparathyroidism Treatment (SHPT) Market Size, Share, Growth Analysis, By Drug Analysis(hospital & retail pharmacies, online channel, and other), By Region - Industry Forecast 2024-2031

Report ID: SQMIC35J2108 | Region: Country | Published Date: February, 2024
Pages: 157 | Tables: 36 | Figures: 74

US Secondary Hyperparathyroidism Treatment (SHPT) Market News

  • In Feb 2022, OPKO Health, Inc. (NASDAQ: OPK) announces that Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has initiated the commercial launch of RAYALDEE (extended release calcifediol) in Germany, the first launch of RAYALDEE outside the U.S. 
  • In April 2022, Pathalys Pharma, Inc., a private, late-stage biopharma company committed to the development and commercialization of a range of best-in-class therapies for patients with end stage kidney disease (ESKD), today announced plans for a phase 3 program to support the application of upacicalcet (designated PLS240 for clinical trials), globally. 
$3,500
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

US Secondary Hyperparathyroidism Treatment (SHPT) Market size was valued at USD 4.59 billion in 2019 and is poised to grow from USD 5 billion in 2023 to USD 9.97 billion by 2031, growing at a CAGR of 9% in the forecast period (2024-2031).

Amgen Inc. holds 40% of the US secondary hyperparathyroidism therapy (SHPT) market thanks to its substantial strategic decisions and robust pharmaceutical portfolio. SHPT is treated with Sensipar (Cinacalcet), a well-liked medication from Amgen. Generic manufacturers have only recently begun to enter the market as a result of numerous treatments' expiration of their patents. Organizations like Teva Pharmaceutical Industries Ltd., Abbvie, and Sandoz are among the market players. SHPT market expansion is also anticipated to be fueled by expanding generic manufacturer competition during the anticipated time frame. ' Amgen Inc. ', ' Sanofi S.A. ', ' F. Hoffmann-La Roche Ltd ', ' AbbVie Inc. ', ' Pfizer Inc. ', ' Bayer AG ', ' AstraZeneca Plc ', ' Eli Lilly and Company ', ' Johnson & Johnson ', ' Teva Pharmaceutical Industries Ltd. ', ' Novartis AG ', ' GlaxoSmithKline Plc ', ' Merck & Co., Inc. ', ' Bristol-Myers Squibb Company ', ' Takeda Pharmaceutical Company Ltd. ', ' Boehringer Ingelheim International GmbH ', ' Daiichi Sankyo Company, Limited ', ' Astellas Pharma Inc. ', ' Ipsen Biopharmaceuticals, Inc. ', ' Mallinckrodt Pharmaceuticals '

SHPT development occurs simultaneously with vitamin D deficiency. Over 97% of ESRD patients, according to OPKO Health, Inc., show signs of vitamin D deficiency, which is a key sign that SHPT is developing in the patient. As a result, it is anticipated that the increase in the number of chronic illnesses brought on by sedentary lifestyles will drive the SHPT treatment market in the United States. The secondary hyperparathyroidism (SHPT) treatment market in the United States is also significantly influenced by the government's initiative to develop standards for better treatment management. The control of biochemical indicators of mineral and bone metabolism, which have a strong epidemiologic connection to cardiovascular events and bone fractures, is the goal of SHPT therapy.

As medical professionals and clinical specialists have become more aware of the condition, the management plan for SHPT has been improved.The growth of the market for treatments for CKD and ESRD would benefit from the early detection and evaluation of secondary hyperparathyroidism for mineral metabolism. The market is expected to grow more quickly during the projection period because there will be fewer issues with SHPT management.

Geographically, the West, Midwest, South, and Northeast areas make up the U.S. SHPT therapy market. The South region brought in USD 1.93 billion in revenue and is expected to take the lead in the US market over the next several years. The South region's dominance can be attributed to the existence of a large number of dialysis facilities and the strategic positioning of top dialysis clinic networks like Fresenius Care, DaVita, etc. in the area. Additionally, due to the high incidence of older people with kidney disorders, the southern region of the United States has the highest prevalence of secondary hyperparathyroidism.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

U.S. Secondary Hyperparathyroidism (SHPT) Treatment Market
Buy Now GET FREE SAMPLE
Thyroid Gland Disorders Treatment Market
Buy Now GET FREE SAMPLE
Hormone Replacement Therapy (HRT) Market
Buy Now GET FREE SAMPLE
Hyperphosphatemia Therapeutics Market
Buy Now GET FREE SAMPLE
Growth Hormone Deficiency Market
Buy Now GET FREE SAMPLE
Thyroid Function Test Market
Buy Now GET FREE SAMPLE
Human Growth Hormone Market
Buy Now GET FREE SAMPLE
Continuous Renal Replacement Therapy Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

US Secondary Hyperparathyroidism Treatment(SHPT) Market

Report ID: SQMIC35J2108

$3,500
BUY NOW GET FREE SAMPLE